Literature DB >> 31204529

Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.

Milos D Miljkovic1, Mark Roschewski1, Kieron Dunleavy1,2, Wyndham H Wilson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31204529      PMCID： PMC6917991          DOI： 10.1080/10428194.2019.1627540

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Authors:  Peter Martin; Nancy L Bartlett; Kristie A Blum; Steven Park; Kami Maddocks; Jia Ruan; LeAnn Ridling; Christopher Dittus; Zhengming Chen; Xiangao Huang; Giorgio Inghirami; Maurizio DiLiberto; Selina Chen-Kiang; John P Leonard
Journal:  Blood       Date:  2019-01-28       Impact factor: 22.113

2.  Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Authors:  John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

3.  The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.

Authors:  Matthew D Seftel; John Kuruvilla; Tom Kouroukis; Versha Banerji; Graeme Fraser; Michael Crump; Rajat Kumar; Haji I Chalchal; Muhammad Salim; Rob C Laister; Susan Crocker; Spencer B Gibson; Marcia Toguchi; John F Lyons; Hao Xu; Jean Powers; Joana Sederias; Lesley Seymour; Annette E Hay
Journal:  Leuk Lymphoma       Date:  2016-10-17

4.  Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  C Tom Kouroukis; Andrew Belch; Michael Crump; Elizabeth Eisenhauer; Randy D Gascoyne; Ralph Meyer; Reinhard Lohmann; Pedro Lopez; Jean Powers; Robert Turner; Joseph M Connors
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

5.  Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Authors:  Antoinette R Tan; Donna Headlee; Richard Messmann; Edward A Sausville; Susan G Arbuck; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

6.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.

Authors:  Jeffrey R Infante; Philippe A Cassier; John F Gerecitano; Petronella O Witteveen; Rashmi Chugh; Vincent Ribrag; Abhijit Chakraborty; Alessandro Matano; Jason R Dobson; Adam S Crystal; Sudha Parasuraman; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2016-08-19       Impact factor: 12.531

Review 7.  Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

Authors:  Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

8.  Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.

Authors:  Thomas S Lin; Orion M Howard; Donna S Neuberg; Helen H Kim; Margaret A Shipp
Journal:  Leuk Lymphoma       Date:  2002-04

9.  Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.

Authors:  Joyoti Dey; Thomas L Deckwerth; William S Kerwin; Joseph R Casalini; Angela J Merrell; Marc O Grenley; Connor Burns; Sally H Ditzler; Chantel P Dixon; Emily Beirne; Kate C Gillespie; Edward F Kleinman; Richard A Klinghoffer
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

10.  Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).

Authors:  D C Phillips; Y Xiao; L T Lam; E Litvinovich; L Roberts-Rapp; A J Souers; J D Leverson
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037
View more
  1 in total

Review 1.  Altered pathways and targeted therapy in double hit lymphoma.

Authors:  Yuxin Zhuang; Jinxin Che; Meijuan Wu; Yu Guo; Yongjin Xu; Xiaowu Dong; Haiyan Yang
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.